The Filing Desk

Puma Biotechnology vs Vanda Pharmaceuticals

Puma Biotechnology PBYI · Vanda Pharmaceuticals VNDA · Pharmaceuticals

Puma Biotechnology reported revenue of $228 million in fiscal 2025, about the same as Vanda Pharmaceuticals' $216 million in fiscal 2025. Puma Biotechnology's revenue fell 0.9% in its latest year, and Vanda Pharmaceuticals' grew 8.7%. Puma Biotechnology had an operating margin of 16.3%, against -70.0% at Vanda Pharmaceuticals. Free cash flow was $42 million at Puma Biotechnology and −$110 million at Vanda Pharmaceuticals.

Side by side

Puma BiotechnologyVanda Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$228M$216M
Revenue growth−0.9%8.7%
Revenue growth a year, last 5 years0.3%−2.7%
Gross margin74.5%—
Operating margin16.3%−70.0%
Net margin13.6%−102.0%
Free cash flow$42M−$110M
Free cash flow margin18.3%−51.1%
Return on capital48.2%—
Net debt to EBITDA−1.4x—
Dividends and buybacks$0M$0M
Change in diluted share count3.2%1.3%
Last close$7.12$3.67
P/E at the last close15.5×—
Insider trades, last 12 monthssold $2.0 millionsold $2.8 million
Piotroski F-score8 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Puma BiotechnologyVanda Pharmaceuticals
Operating margin
Percent of revenue
Puma BiotechnologyVanda Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Puma BiotechnologyVanda Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Puma Biotechnology and Vanda Pharmaceuticals pages.